Caribou Biosciences (CRBU) Non Operating Investment Income (2022 - 2024)
Caribou Biosciences' (CRBU) quarterly Non Operating Investment Income came in at -$14000.0 in Q3 2024, down 250.0% year-on-year from $9333.3 in Q4 2023, and up 86.27% on a QoQ basis from -$102000.0 in Q2 2024.
Caribou Biosciences (CRBU) Non Operating Investment Income (2022 - 2024) Analysis & Trends
Caribou Biosciences (CRBU) has 3 years of Non Operating Investment Income data on file, last reported at -$14000.0 in Q3 2024.
- On a quarterly basis, Non Operating Investment Income fell 250.0% year-over-year to -$14000.0 in Q3 2024; TTM through Sep 2024 was -$125000.0, a 119.3% decrease from a year earlier, with the FY2023 full-year figure at -$6000.0, up 95.49% from the prior year.
- Non Operating Investment Income for Q3 2024 stood at -$14000.0, up from -$102000.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for CRBU reached as high as $31000.0 in Q3 2022 and fell as low as -$102000.0 in Q2 2024.
- Historically, Non Operating Investment Income has averaged -$25500.0 across 3 years, with a median of -$14500.0 in 2023.
- Across the five-year window, Non Operating Investment Income jumped 237.5% in 2023 and tumbled 563.64% in 2024, its largest moves.
- Year by year, Non Operating Investment Income stood at -$60000.0 in 2022, then surged by 85.0% to -$9000.0 in 2023, then slumped by 55.56% to -$14000.0 in 2024.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$14000.0 in Q3 2024, -$102000.0 in Q2 2024, and -$9000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Caribou Biosciences | 152.90 Mn | 35.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -14,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -102,000.00 |
| Jun 30, 2024 | -102,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Mar 31, 2023 | -15,000.00 |
| Mar 31, 2023 | -15,000.00 |
| Dec 31, 2022 | -60,000.00 |
| Dec 31, 2022 | -60,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | -16,000.00 |
| Jun 30, 2022 | -16,000.00 |
| Mar 31, 2022 | -88,000.00 |
| Mar 31, 2022 | -88,000.00 |